CRISPR-edited GD2 CAR-T / University of Wisconsin - Madison - LARVOL DELTA

Cellares and UW-Madison partner to automate manufacturing for novel solid tumor CAR-T (Drug Discovery & Development) - "...Cellares is partnering with the University of Wisconsin School of Medicine and Public Health to automate the clinical-scale manufacturing of UW-Madison’s novel CRISPR-edited GD2 CAR-T therapy. The goal is to accelerate this potential solid tumor treatment into clinical trials more swiftly. The partnership specifically targets the manufacturing bottlenecks that can hinder therapies like UW-Madison’s CRISPR-edited GD2 CAR-T, designed for solid tumors such as neuroblastoma and melanoma. By leveraging Cellares’ Cell Shuttle platform - an integrated, automated system - the collaboration provides UW-Madison access to reproducible, clinical-scale production capabilities crucial for advancing their cutting-edge research from the lab bench towards essential human trials, bypassing traditional development delays."

Licensing / partnership • Melanoma • Neuroblastoma